98%
921
2 minutes
20
Background And Objective: Infusion containing paracetamol, alizapride, ketorolac and tramadol is used after a general anaesthesia in order to limit pain, fever and nausea. Currently, these infusions are prepared according to demand in the anaesthesia unit, but the preparation in advance could improve quality of preparation and time management. The aim of this study was to investigate the long-term stability of this infusion in glass bottles at 5°C ± 3 °C.
Method: Five bottles of infusion were stored at 5°C ± 3 °C for 60 days. A visual and microscope inspection were performed periodically to observe any particle appearance or colour change. pH and absorbance at three wavelengths were measured. The concentrations were measured by ultra-high performance liquid chromatography - diode array detection.
Results: Multiple verifications were performed during the first 35 days and no crystal, impurity or colour change were observed. At the next time point (42nd day), crystals were visible to the naked eye. pH and absorbance at 350 nm and 550 nm were stable. A slight increase in the absorbance at 410 nm was observed during the study, suggesting that a degradation product could be formed and absorb at this wavelength. The infusion was considered chemically stable while the lower one-sided prediction limit at 95% remains superior to 90% of the initial concentration. Concentration measurements demonstrated that ketorolac and alizapride remained stable in the infusion for 35 days. The stability of tramadol was 28 days. However, degradation of paracetamol was much faster given that concentration has fallen below 90% of the initial concentration after 7 days.
Conclusion: Infusion of paracetamol, alizapride, ketorolac and tramadol remains stable for 7 days in glass bottles at 5°C ± 3 °C and could be prepared in advance with these storage conditions.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147551 | PMC |
http://dx.doi.org/10.1136/ejhpharm-2019-001966 | DOI Listing |
BMC Anesthesiol
August 2025
Department of Pharmacy Practice, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt.
Background: Postoperative pain control in neurosurgical patients particularly after elective craniotomy remains clinically challenging due to the need for early neurological assessment and the adverse effects associated with opioid use. This study aimed to compare the efficacy and safety of an opioid-sparing multimodal analgesia (MMA) protocol versus a conventional opioid-based regimen for managing post-craniotomy pain.
Methodology: This prospective, randomized controlled trial was conducted over 12 months at Zagazig University Hospitals and included 60 adult patients (aged 18–65 years, American Society of Anesthesiologists )ASA( physical status I–II) scheduled for elective supratentorial craniotomy with planned postoperative intensive care unit (ICU) admission.
Emerg Med J
August 2025
The University of Edinburgh Centre for Cardiovascular Science, Edinburgh, UK.
Background: Treatment with the 12-hour Scottish and Newcastle Antiemetic Protocol (SNAP) acetylcysteine regimen is associated with decreased length of stay and fewer anaphylactoid reactions in adult patients, and the protocol is now recommended by several UK organisations and used widely. One potential barrier to adoption is concern regarding the potential for variation in protocol performance with patient age. Anecdotally, this has led to slower adoption in paediatric settings.
View Article and Find Full Text PDFMult Scler J Exp Transl Clin
August 2025
Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
Background: Multiple sclerosis (MS), a chronic neurological disease, is typically managed with disease-modifying therapies (DMTs) to reduce relapse rates and slow disease progression. Some of these DMTs can cause infusion-related reactions (INRRs), which range from mild symptoms to severe allergic reactions. Corticosteroids are commonly used in premedication regimens to mitigate INRRs.
View Article and Find Full Text PDFCureus
July 2025
Anesthesiology and Perioperative Medicine, West Virginia University School of Medicine, Morgantown, USA.
Ehlers-Danlos Syndrome (EDS) is a group of inherited, autosomal dominant connective tissue disorders caused by defects in procollagen and collagen production. Vascular EDS, also known as type 4 EDS, involves mutations in the COL3A1 gene, resulting in fragile vascular tissues and compromised organ integrity, which pose significant challenges during both labor and anesthesia. We report the case of a 19-year-old female patient with type 4 EDS, opioid-induced seizures, and a family history of malignant hyperthermia, who presented to the labor ward at 37 weeks of gestation.
View Article and Find Full Text PDFAnn Hematol
July 2025
Division of Hematology, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
Rituximab is a monoclonal antibody used in the treatment of B-cell malignancies. Infusion reactions are common during the first exposure but decrease with subsequent infusions. We here present our experience with a protocol for a 30-minute intravenous infusion of rituximab (SpeedR) to patients who have previously tolerated a 90-minute rituximab infusion.
View Article and Find Full Text PDF